Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model

• Daniela Maisel ,

  * E-mail: daniela.maisel@roche.com

  Affiliation Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Fabian Birzele,

  Affiliation Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Edgar Voss,

  Current address: Centralized and Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany

  Affiliation Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Adam Nopora,

  Affiliation Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Sabine Bader,

  Affiliation Translational Technologies and Bioinformatics, Pharmaceutical Sciences, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Thomas Friess,

  Affiliation Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Bernhard Goller,

  Affiliation Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany

  ⨯
• Daphna Laifenfeld,

  Affiliation Selventa Inc., Cambridge, Massachusetts, 02140, United States of America

  ⨯
• Stefan Weigand,

  Affiliation Large Molecule Research, Roche Innovation Center Basel, Basel, Switzerland

  ⨯
• Valeria Runza

  Affiliation Discovery Oncology, Roche Innovation Center Munich, Penzberg, Germany

  ⨯